Zymeworks Inc. announced Dr. Jeffrey Smith has been promoted to Executive Vice President and Chief Medical Officer, where he will play a key role in leading the clinical development of early-stage programs and overseeing integrated global early-stage development group. Dr. John Fann has been promoted to Senior Vice President, Process Sciences, where he will continue to play a key role in supporting the advancement of new product candidates from preclinical studies into clinical trials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9 USD | -2.60% | -1.32% | -13.38% |
May. 02 | Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.38% | 641M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc Announces Additional Leadership Appointments